Neovacs SA (FR:ALNEV) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neovacs SA, a French biotech firm focusing on inflammatory and autoimmune diseases, has partnered with CNRS’s UTCBS to develop mRNA vaccine delivery methods for asthma treatment. The collaboration, which Neovacs will exclusively fund for 100 k€, aims to create lipid formulations for human and veterinary vaccines. The company is recognized by the CNRS for its R&D efforts in the field of active immunotherapy through its kinoid® technology platform.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.